Reducing mortality in sepsis: new directions
暂无分享,去创建一个
Djillali Annane | Edward Abraham | G. Van den Berghe | D. Annane | G. Bernard | J. Vincent | E. Abraham | E. Rivers | Greet Van den Berghe | Jean-Louis Vincent | Gordon Bernard | Emanuel Rivers
[1] J. E. Carceller. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis , 1999 .
[2] C. Sprung,et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .
[3] J. Vincent,et al. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. , 1999, Critical care medicine.
[4] Gordon R. Bernard,et al. Treating patients with severe sepsis. , 1999, New England Journal of Medicine.
[5] José A Fernández,et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications , 2000, Critical care medicine.
[6] G. Chrousos,et al. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. , 2002, American journal of respiratory and critical care medicine.
[7] I. Chaudry,et al. Adrenal insufficiency during the late stage of polymicrobial sepsis , 1999, Critical care medicine.
[8] R. Waldrop,et al. Critical care provided in an urban emergency department. , 1998, The American journal of emergency medicine.
[9] G. Clermont,et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.
[10] Derek C. Angus,et al. Epidemiology of sepsis: An update , 2001, Critical care medicine.
[11] R. Balk,et al. SEVERE SEPSIS AND SEPTIC SHOCK , 2000 .
[12] G. Koch,et al. Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .
[13] M Schetz,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[14] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[15] B. Bistrian,et al. Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.
[16] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[17] D. Powars,et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] P. Pelosi,et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. , 1996, The New England journal of medicine.
[19] R. Lefering,et al. Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.
[20] S. Nasraway,et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.
[21] P. Bollaert,et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.
[22] M. Haller,et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.
[23] Véronique Sébille,et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock , 2002 .
[24] C. Sprung,et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.
[25] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.
[26] L. Thijs,et al. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma , 2001, Intensive Care Medicine.
[27] Arthur S Slutsky,et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. , 1999, JAMA.
[28] A. Chang,et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.
[29] K. Steinberg,et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. , 1995, JAMA.
[30] M. Blombäck,et al. Protein C, Protein S and c4b-Binding Protein in Severe lnfection and Septic Shock , 1991, Thrombosis and Haemostasis.
[31] J. Helterbrand,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .
[32] Arthur S Slutsky,et al. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. , 1997, The Journal of clinical investigation.
[33] H. Nguyen,et al. Critical care in the emergency department: A physiologic assessment and outcome evaluation. , 2000, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[34] E. Ivers,et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .
[35] C. Carvalho,et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.
[36] D. Cook,et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.
[37] J. McCutchan,et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1983, The New England journal of medicine.
[38] Lessening the punch of heparin-induced thrombocytopenia. , 2002, Chest.
[39] T. Butler,et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.
[40] G. Bernard,et al. Airway and lung in sepsis , 2001, Intensive Care Medicine.
[41] J. Martin,et al. National Vital Statistics Reports , 2002 .
[42] D. Annane,et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.
[43] G. Van den Berghe,et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.
[44] R. Bone. Gram-negative sepsis: a dilemma of modern medicine , 1993, Clinical Microbiology Reviews.
[45] C. Hinds,et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.
[46] D. Schoenfeld,et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.
[47] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[48] G. Van den Berghe,et al. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.
[49] J. Vincent. Need for intensivists in intensive-care units , 2000, The Lancet.
[50] J. Helterbrand,et al. Low levels of protein C are associated with poor outcome in severe sepsis. , 2001, Chest.
[51] A. Morris,et al. Care A H Morris environments Decision support and safety of clinical , 2002 .
[52] P. Pelosi,et al. A Trial of Goal-Oriented Hemodynamic Therapy in Critically Ill Patients , 1995 .
[53] C. Esmon,et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. , 2000, Blood.